Raised circulating tenascin-C in rheumatoid arthritis

Arthritis Research and Therapy

Volumn 14, Issue 6, 2012, Pages

  Page, Theresa H ^a   Charles, Peter J ^a   Piccinini, Anna M ^a   Nicolaidou, Vicky ^a   Taylor, Peter C ^a   Midwood, Kim S ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; METHOTREXATE; PLACEBO; TENASCIN; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATORY DISEASE; MULTICENTER STUDY; MYOSITIS; PHASE 2 CLINICAL TRIAL; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; ARTHRITIS, RHEUMATOID; BLOOD; COHORT ANALYSIS; DRUG COMBINATION; MALE; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY; WESTERN BLOTTING; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BLOTTING, WESTERN; COHORT STUDIES; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; METHOTREXATE; MIDDLE AGED; MYOSITIS; SJOGREN'S SYNDROME; SPONDYLITIS, ANKYLOSING; TENASCIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84870061759     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4105     Document Type: Article

References (34)

1. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M, Emery P, Gibofsky A, Gomez-Reino JJ, Haraoui B, Kalden J, Keystone EC, Kvien TK, McInnes I, Martin-Mola E, Montecucco C, Schoels M, van der Heijde D. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010, 69:631-637. 10.1136/ard.2009.123919, 3015099, 20215140.
2. Isaacs JD, Ferraccioli G. The need for personalised medicine for rheumatoid arthritis. Ann Rheum Dis 2011, 70:4-7. 10.1136/ard.2010.135376, 21068091.
3. Miossec P, Verweij CL, Klareskog L, Pitzalis C, Barton A, Lekkerkerker F, Reiter S, Laslop A, Breedveld F, Abadie E, Flamion B, Dere W, Mpofu S, Goel N, Ethgen D, Mitlak B, Ormarsdottir S, Rao R, Tsouderos Y, Reginster JY. Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. Ann Rheum Dis 2011, 70:1713-1718. 10.1136/ard.2011.154252, 21784723.
4. Udalova IA, Ruhmann M, Thomson SJ, Midwood KS. Expression and immune function of tenascin-C. Crit Rev Immunol 2011, 31:115-145. 10.1615/CritRevImmunol.v31.i2.30, 21542790.
5. Midwood KS, Orend G. The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal 2009, 3:287-310. 10.1007/s12079-009-0075-1, 2778592,2778592, 19838819.
6. Midwood K, Sacre S, Piccinini AM, Inglis J, Trebaul A, Chan E, Drexler S, Sofat N, Kashiwagi M, Orend G, Brennan F, Foxwell B. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 2009, 15:774-780. 10.1038/nm.1987, 19561617.
7. Kanayama M, Kurotaki D, Morimoto J, Asano T, Matsui Y, Nakayama Y, Saito Y, Ito K, Kimura C, Iwasaki N, Suzuki K, Harada T, Li HM, Uehara J, Miyazaki T, Minami A, Kon S, Uede T. Alpha9 integrin and its ligands constitute critical joint microenvironments for development of autoimmune arthritis. J Immunol 2009, 182:8015-8025. 10.4049/jimmunol.0900725, 19494327.
8. Kanayama M, Morimoto J, Matsui Y, Ikesue M, Danzaki K, Kurotaki D, Ito K, Yoshida T, Uede T. alpha9beta1 integrin-mediated signaling serves as an intrinsic regulator of pathogenic Th17 cell generation. J Immunol 2011, 187:5851-5864. 10.4049/jimmunol.1101524, 22039306.
9. Ruhmann M, Piccinini AM, Kong PL, Midwood KS. Endogenous activation of adaptive immunity: Tenascin-C drives IL-17 synthesis in arthritic joint disease. Arthritis Rheum 2012, 64:2179-2190. 10.1002/art.34401, 22275298.
10. Goh FG, Piccinini AM, Krausgruber T, Udalova IA, Midwood KS. Transcriptional regulation of the endogenous danger signal tenascin-C: a novel autocrine loop in inflammation. J Immunol 2010, 184:2655-2662. 10.4049/jimmunol.0903359, 20107185.
11. McCachren SS, Lightner VA. Expression of human tenascin in synovitis and its regulation by interleukin-1. Arthritis Rheum 1992, 35:1185-1196. 10.1002/art.1780351011, 1384510.
12. Chevalier X, Groult N, Larget-Piet B, Zardi L, Hornebeck W. Tenascin distribution in articular cartilage from normal subjects and from patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 1994, 37:1013-1022. 10.1002/art.1780370706, 7517675.
13. Cutolo M, Picasso M, Ponassi M, Sun MZ, Balza E. Tenascin and fibronectin distribution in human normal and pathological synovium. J Rheumatol 1992, 19:1439-1447.
14. Salter DM. Tenascin is increased in cartilage and synovium from arthritic knees. Br J Rheumatol 1993, 32:780-786. 10.1093/rheumatology/32.9.780, 7690296.
15. Hasegawa M, Hirata H, Sudo A, Kato K, Kawase D, Kinoshita N, Yoshida T, Uchida A. Tenascin-C concentration in synovial fluid correlates with radiographic progression of knee osteoarthritis. J Rheumatol 2004, 31:2021-2026.
16. Hasegawa M, Nakoshi Y, Muraki M, Sudo A, Kinoshita N, Yoshida T, Uchida A. Expression of large tenascin-C splice variants in synovial fluid of patients with rheumatoid arthritis. J Orthop Res 2007, 25:563-568. 10.1002/jor.20366, 17262825.
17. Taylor PC, Steuer A, Gruber J, McClinton C, Cosgrove DO, Blomley MJ, Marsters PA, Wagner CL, Maini RN. Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. Arthritis Rheum 2006, 54:47-53. 10.1002/art.21544, 16385521.
18. Sato A, Aonuma K, Imanaka-Yoshida K, Yoshida T, Isobe M, Kawase D, Kinoshita N, Yazaki Y, Hiroe M. Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction. J Am Coll Cardiol 2006, 47:2319-2325. 10.1016/j.jacc.2006.03.033, 16750702.
19. Terasaki F, Okamoto H, Onishi K, Sato A, Shimomura H, Tsukada B, Imanaka-Yoshida K, Hiroe M, Yoshida T, Kitaura Y, Kitabatake A. Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy. Circ J 2007, 71:327-330. 10.1253/circj.71.327, 17322629.
20. Tanaka H, El-Karef A, Kaito M, Kinoshita N, Fujita N, Horiike S, Watanabe S, Yoshida T, Adachi Y. Circulating level of large splice variants of tenascin-C is a marker of piecemeal necrosis activity in patients with chronic hepatitis C. Liver Int 2006, 26:311-318. 10.1111/j.1478-3231.2005.01229.x, 16584393.
21. Riedl S, Tandara A, Reinshagen M, Hinz U, Faissner A, Bodenmuller H, Buhr HJ, Herfarth C, Moller P. Serum tenascin-C is an indicator of inflammatory bowel disease activity. Int J Colorectal Dis 2001, 16:285-291. 10.1007/s003840100312, 11686525.
22. Schenk S, Muser J, Vollmer G, Chiquet-Ehrismann R. Tenascin-C in serum: an acute-phase protein or a carcinoma marker?. Int J Cancer 1995, 60:145. 10.1002/ijc.2910600121, 7529210.
23. Perrotta R, Bevelacqua Y, Malaguarnera G, Paladina I, Giordano M, Malaguarnera M. Serum markers of cutaneous melanoma. Front Biosci (Elite Ed) 2010, 2:1115-1122.
24. Amonkar SD, Bertenshaw GP, Chen TH, Bergstrom KJ, Zhao J, Seshaiah P, Yip P, Mansfield BC. Development and preliminary evaluation of a multivariate index assay for ovarian cancer. PLoS One 2009, 4:e4599. 10.1371/journal.pone.0004599, 2643010, 19240799.
25. Ishiwata T, Takahashi K, Shimanuki Y, Ohashi R, Cui R, Takahashi F, Shimizu K, Miura K, Fukuchi Y. Serum tenascin-C as a potential predictive marker of angiogenesis in non-small cell lung cancer. Anticancer Res 2005, 25:489-495.
26. Schenk S, Muser J, Vollmer G, Chiquet-Ehrismann R. Tenascin-C in serum: a questionable tumor marker. Int J Cancer 1995, 61:443-449. 10.1002/ijc.2910610402, 7538974.
27. Midwood KS, Hussenet T, Langlois B, Orend G. Advances in tenascin-C biology. Cell Mol Life Sci 2011, 68:3175-3199. 10.1007/s00018-011-0783-6, 3173650, 21818551.
28. Oskarsson T, Acharyya S, Zhang XH, Vanharanta S, Tavazoie SF, Morris PG, Downey RJ, Manova-Todorova K, Brogi E, Massague J. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med 2011, 17:867-874. 10.1038/nm.2379, 21706029.
29. Tremble P, Chiquet-Ehrismann R, Werb Z. The extracellular matrix ligands fibronectin and tenascin collaborate in regulating collagenase gene expression in fibroblasts. Mol Biol Cell 1994, 5:439-453. 301053, 7519905.
30. van den Berg WB, Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol 2009, 5:549-553. 10.1038/nrrheum.2009.179, 19798029.
31. Lubberts E, Joosten LA, Oppers B, van den Bersselaar L, Coenen-de Roo CJ, Kolls JK, Schwarzenberger P, van de Loo FA, van den Berg WB. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol 2001, 167:1004-1013.
32. van Hamburg JP, Mus AM, de Bruijn MJ, de Vogel L, Boon L, Cornelissen F, Asmawidjaja P, Hendriks RW, Lubberts E. GATA-3 protects against severe joint inflammation and bone erosion and reduces differentiation of Th17 cells during experimental arthritis. Arthritis Rheum 2009, 60:750-759. 10.1002/art.24329, 19248112.
33. Latijnhouwers MA, de Jongh GJ, Bergers M, de Rooij MJ, Schalkwijk J. Expression of tenascin-C splice variants by human skin cells. Arch Dermatol Res 2000, 292:446-454. 10.1007/s004030000152, 11000288.
34. Nakoshi Y, Hasegawa M, Sudo A, Yoshida T, Uchida A. Regulation of tenascin-C expression by tumor necrosis factor-alpha in cultured human osteoarthritis chondrocytes. J Rheumatol 2008, 35:147-152.